Medpace

#1598

Rank

$10.78B

Marketcap

United States

Country

Leadership team

Dr. August James Troendle M.D. (Chairman & CEO)

Mr. Jesse J. Geiger BBA, CPA (Pres)

Mr. Kevin M. Brady (CFO & Treasurer)

Products/ Services

Biotechnology, Pharmaceutical

Number of Employees

1,000 - 20,000

Headquarters

Cincinnati, Ohio, United States

Established

1992

Company Registration

SEC CIK number: 0001668397

Net Income

100M - 500M

Revenue

Above - 1B

Traded as

MEDP

Social Media

URL

https://www.medpace.com

Overview

Location

Recognition and Award

References

Summary

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

History

Dr. August Troendle founded Medpace in Cincinnati, Ohio in 1992 as Medical Research Services. Dr. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol.

With a team of industry physicians, Dr. Jonathan Issacsohn and Dr. Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, the late Dr. David Orloff was regarded as an industry opinion leader in the study of metabolic diseases - most specifically diabetes and obesity. Dr. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce.Medpace completed construction on a new campus in 2012 in Madisonville, a village in the city of Cincinnati. This was a project completed in cooperation with Madisonville, the City of Cincinnati Department of Economic Development, and the State of Ohio. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED certified campus.

Acquisitions

2007-Medpace acquires Monax in the Czech Republic

2009-Medpace acquires PharmaBrains AG in Switzerland

2010-Medpace acquires Symbios, a medical device consultancy in Minneapolis, MN

2010-Medpace acquires Medical Consulting Dr. Schlichtiger, GmbH, in Germany

2012-Medpace acquires MediTech BV, a medical device consultancy in the Netherlands.

Mission

Our mission is to accelerate the global development of safe and effective medical therapeutics through high-quality, comprehensive, and compliant clinical research services.

Vision

Uncompromising Commitment to Research Our unique global partnering philosophy emphasizes an uncompromising commitment to clinical research and to the highest level of ethical standards and performance in our jobs. We are selective about the projects we engage in because we are devoted to quality and providing our partners with best-in-class service. Medpace's dedicated teams serve as an extension of your team ' we engage quickly and provide strategic thinking ' ensuring quicker start-up times, superior quality, and the most efficient delivery of every phase of your clinical trial. Our therapeutic and regulatory experts are committed to streamlining your path to approval so every partnership is designed to create research solutions focused on your critical needs.

Key Team

Ms. Susan E. Burwig (Exec. VP of Operations)

Mr. Stephen P. Ewald (Chief Compliance Officer, Gen. Counsel & Corp. Sec.)

Brandon Ebken (Chief Information Officer)

Ms. Lauren Morris (Associate Director of Investors Relations)

Mr. Todd Meyers (VP of Bus. Devel. & Marketing)

Mr. Weimin Gai MS (Sr. VP of Biometrics)

Mr. Daniel O'Leary (Sr. VP of Medical Department)

Recognition and Awards

Medpace has been recognized for numerous awards, most recently receiving the Quality Service Provider Award from AstraZeneca. We are also proud to be certified to both ISO 9001:2008 and ISO/IEC 270001:2005 standards.